|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Artera AI Platform in Prostate Cancer
|
Andre Esteva, Ph.D. and Felix Feng, MD
Andrea Esteva and Felix Feng join Alicia Morgans to discuss the Artera platform in prostate cancer intended to identify patients who will benefit from therapy intensification and help guide treatment decisions for men with localized prostate cancer. |
|
|
|
|
|
|
|
|
|
|
| Beyond Genomics: AI Informing Decision Making in Prostate Cancer |
Ashley Ross, MD, PhD
Alicia Morgans and Ashley Ross discuss the current clinical landscape of how risk is defined in localized prostate cancer highlighting a novel artificial intelligence (AI) derived digital pathology-based biomarker test for prostate cancer, Artera. |
|
|
|
|
|
|
|
|
|
|
| Artera Launches with $90 Million in Funding to Personalize Cancer Therapy with Multimodal AI
|
|
|
| Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launches publicly with $90M in funding. The investment comes from a syndicate of prominent tech and healthcare investors, comprised of seven institutions and and angel investors. This announcement comes on the heels of Artera’s recently released, positive data at ASCO GU 2023, highlighting that the prognostic biomarker was validated across six phase III randomized trials.
|
|
|
|
|
|
| Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker in High-Risk Prostate Cancer: Results from Six NRG/RTOG Phase III Randomized Trials |
| Daniel Spratt, MD |
| This novel multi-modal artificial intelligence prognostic biomarker was successfully validated across six phase III randomized trials with long-term follow-up to be independently prognostic over standard clinical and pathologic variables for men with high-risk prostate cancer. Despite all patients having high-risk disease, the multi-modal artificial intelligence biomarker identified those with highly variable risks for distant metastasis and prostate cancer-specific mortality. |
|
|
|
|
|
| External Validation of a Digital Pathology-Based AI Model Predicting Metastasis and Death in High and Very High Risk Men on NRG/RTOG 9902 Phase III Trial
|
| Ashley Ross, MD, Ph.D.
|
| MMAI prognostic models outperform clinical and pathologic variables, albeit when compared individually, for the prediction of distant metastases and prostate cancer-specific mortalities in a population of men with localized high-risk prostate cancer. This study provides further support to the clinical use of MMAI models to improve prognostication in high-risk patients and allow for an individualized, risk-adapted treatment approach.
|
|
|
|
|
|
| Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology |
| Jonathan Tward, MD, PhD, FASTRO |
| AI-derived prognostic biomarkers provide personalized risk estimates, that when grouped allows more streamlined communication. Jonathan Tward discusses prostate cancer risk stratification using multimodal deep learning with digital histopathology, within the context of NRG Oncology phase III trials. |
|
|
|
|
|
